Trade EDIT

Editas Medicine, Inc.

-

00:00:00

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Read more...

1D Change

-0.596%

Why BlackBull Markets?

26k+

Tradable Assets

1:500

Leverage up to

Regulated

Multi-Regulated

24/7

Customer Support

$0

No Minimum Deposit

TRADING CONDITIONS

EDIT
TRADING CONDITIONS

Digits

3

Point

0.001

Spread

 
floating

Contract Size

1

Volume Min

1

Volume Max

10,000

Volume Step

1

Swap Long (Points)

 
-3.390

Swap Short (Points)

-1.960
Available on
MT5, TV, cTrader
Last update at June 21, 20:08 GMT+3
*Data Source: MT5 Server Prime Account Pricing

Margin Calculator

Calculation Results

Current Price

5.07

Required Margin

Converted Currency

Required Margin

Account Base Currency

How it works:

Use our margin calculator to determine the funds required to open and maintain positions.

Select your account base currency, an asset pair, the size of your position in lots, and your level of leverage. 


The calculation is carried out as follows:
Required Margin = Trade Size / Leverage * Account Currency Exchange Rate

Profit/Loss Calculator

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

How it works:

Use our profit and loss calculator to determine where to place your take profit and stop loss. 

 

Select your account base currency, an asset pair, the size of your position in lots, choose between a long buy and a short sell, and input a stop loss and take profit value. 


The calculation is carried out as follows:
SL / TP Levels = SL, TP Amount / Pip Value Formula * Exchange Rate

Swaps Calculator

Calculation Results

5.07

How it works:

Use our swaps calculator to determine the interest rate differential between two assets. 

 

Select your account base currency, an asset pair, the size of your position in lots. 


The calculation is carried out as follows:
Swap = (One Point / Exchange Rate) * Trade Size (Lot Size) * Swap Value in Points

Currency Calculator

Calculation Results

Loading...

How it works:

Use our currency calculator to determine the value of one currency against another, based on current exchange rates.

Join Now